ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (Tß4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.
Help employers find you! Check out all the jobs and post your resume.
